查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587545

囊腫纖維化治療市場規模、佔有率、趨勢分析報告：按藥物類別、給藥途徑、分銷管道、地區、細分市場預測，2025-2030

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Pancreatic Enzyme Supplements), By Route of Administration (Oral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

囊腫纖維化治療市場的成長與趨勢

Grand View Research, Inc. 的最新報告顯示，預計 2030 年全球囊腫纖維化治療市場規模將達到 227 億美元，2025 年至 2030 年複合年成長率為 14.2%。

全球囊腫纖維化（CF）盛行率的上升、主要企業的研發活動以及非營利組織的有利舉措預計將在預測期內提振市場。

CF 盛行率的增加表明對替代療法的需求不斷增加，從而推動市場走高。在這個市場上經營的主要企業正在與非營利組織合作，專注於開拓新型治療方法的市場。臨床研究中的藥物包括VX-445 + tezacaftor + ivacaftor、PTI-428、QR-010、AZD5634和POL6014。

地方和國家非營利組織的積極努力是推動成長的關鍵因素之一。這些舉措確保為 CF 患者提供支持。這些組織支持這些治療方法的研究和開發工作，並幫助改善這些患者的生活品質。例如，成立於 1986 年的北美囊腫纖維化會議 (NACFC) 為 CF 專業人士提供了一個協作和教育論壇，以共用CF 治療的研究和開發進展。

囊腫纖維化治療市場報告亮點

  • 預計 2024 年全球 CF 治療市場規模將達到 103 億美元，2025 年至 2030 年複合年成長率預計為 14.2%。
  • 囊性纖維化治療藥物佔據市場主導地位，2024年佔最大銷售佔有率，為44.0%。這是因為 Orkambi（一種 CF 治療藥物）已獲得核准，並且有多種臨床實驗藥物正在研發中。
  • 口服給藥的成長推動了市場的成長，由於給藥的簡便性，口服給藥在 2024 年佔據最大的銷售佔有率，達到 69.0%。
  • 由於該地區有大量白人人口，北美佔據了最大的市場佔有率。醫療保健基礎設施、報銷和非營利組織舉措的改善預計將在預測期內推動市場發展。
  • 主要企業包括艾伯維公司(AbbVie Inc.)、羅氏公司(F. Hoffmann-La Roche Ltd.)、吉利德(Gilead)、諾華公司(Novartis AG)、Vertex Pharmaceuticals Inc.、AIT (Advanced Inhalation Therapies) 、Alaxia、梯瓦製藥工業有限公司(Teva Pharmaceutical Industries Ltd)、默克公司(Merck & Co. Inc.) 和Alcresta。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章囊腫纖維化治療市場變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章囊腫纖維化治療市場：藥物類業務分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • CF處理劑
  • 胰酵素補充品
  • 黏液溶解劑
  • 支氣管擴張劑

第5章囊腫纖維化治療市場：途徑途徑業務分析

  • 2024 年及 2030市場佔有率給藥途徑途徑
  • 途徑細分儀表板
  • 2018-2030 年按管理途徑的市場規模、預測與趨勢分析
  • 口服
  • 吸入

第6章囊腫纖維化治療市場：通路業務分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章囊腫纖維化治療市場：區域、估計和趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • AIT（Advanced Inhalation Therapies）
    • Alaxia
    • Teva Pharmaceutical Industries Ltd.
    • Merck &Co. Inc.
    • Alcresta Therapeutics, Inc.
    • AstraZeneca
Product Code: GVR-1-68038-865-7

Cystic Fibrosis Therapeutics Market Growth & Trends:

The global cystic fibrosis therapeutics market size is estimated to reach USD 22.7 billion by 2030, expanding at a CAGR of 14.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Cystic Fibrosis Therapeutics Market Report Highlights:

  • The global CF therapeutics market size was estimated at USD 10.3 billion in 2024 and is expected to grow at a CAGR of 14.2% from 2025 to 2030
  • CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024 owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
  • The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024 due to the ease of administration and convenience
  • North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
  • The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. CFTR Modulators
    • 4.4.1. CFTR Modulators Market, 2018 - 2030 (USD Million)
  • 4.5. Pancreatic Enzyme Supplements
    • 4.5.1. Pancreatic Enzyme Supplements Market, 2018 - 2030 (USD Million)
  • 4.6. Mucolytics
    • 4.6.1. Mucolytics Market, 2018 - 2030 (USD Million)
  • 4.7. Bronchodilators
    • 4.7.1. Bronchodilators Market, 2018 - 2030 (USD Million)

Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 5.5. Inhaled
    • 5.5.1. Inhaled Market, 2018 - 2030 (USD Million)

Chapter 6. Cystic Fibrosis Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Cystic Fibrosis Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamic
      • 7.8.5.2. Regulatory Frameworks
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie Inc.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Gilead
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Vertex Pharmaceuticals Incorporated
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AIT (Advanced Inhalation Therapies)
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Alaxia
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Merck & Co. Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Alcresta Therapeutics, Inc.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AstraZeneca
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cystic Fibrosis Therapeutics Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 Global Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Canada Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Canada Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Mexico Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Europe Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Europe Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 UK Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 UK Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Germany Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Germany Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 France Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 France Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Italy Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Italy Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Spain Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Spain Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Norway Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Norway Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Norway Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Denmark Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Sweden Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Japan Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Japan Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 China Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56 China Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 China Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 India Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 India Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 India Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Australia Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Australia Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65 South Korea Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 South Korea Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Thailand Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Thailand Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 Latin America Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Latin America Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Brazil Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Brazil Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85 South Africa Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91 UAE Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 UAE Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Cystic Fibrosis Therapeutics Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-chain-based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Segment Outlook
  • Fig. 10 Segment Outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Cystic Fibrosis Therapeutics Market Dynamics
  • Fig. 13 Cystic Fibrosis Therapeutics Market: Porter's Five Forces Analysis
  • Fig. 14 Cystic Fibrosis Therapeutics Market: PESTLE Analysis
  • Fig. 15 Cystic Fibrosis Therapeutics Market: Drug Class Segment Dashboard
  • Fig. 16 Cystic Fibrosis Therapeutics Market: Drug Class Market Share Analysis, 2024 & 2030
  • Fig. 17 CFTR Modulators Market, 2018 - 2030 (USD Million)
  • Fig. 18 Pancreatic Enzyme Supplements Market, 2018 - 2030 (USD Million)
  • Fig. 19 Mucolytics Market, 2018 - 2030 (USD Million)
  • Fig. 20 Bronchodilators Market, 2018 - 2030 (USD Million)
  • Fig. 21 Cystic Fibrosis Therapeutics Market: Route of Administration Segment Dashboard
  • Fig. 22 Cystic Fibrosis Therapeutics Market: Route of Administration Market Share Analysis, 2024 & 2030
  • Fig. 23 Oral Market, 2018 - 2030 (USD Million)
  • Fig. 24 Inhaled Market, 2018 - 2030 (USD Million)
  • Fig. 25 Cystic Fibrosis Therapeutics Market: Distribution Channel Segment Dashboard
  • Fig. 26 Cystic Fibrosis Therapeutics Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 27 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail Pharmacies Laboratories Market, 2018 - 2030 (USD Million)
  • Fig. 29 Online Pharmacies Laboratories Market, 2018 - 2030 (USD Million)
  • Fig. 30 Cystic Fibrosis Therapeutics Market Revenue, by Region
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 North America Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Country Dynamics
  • Fig. 35 U.S. Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Country Dynamics
  • Fig. 37 Canada Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico Country Dynamics
  • Fig. 39 Mexico Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 41 UK Country Dynamics
  • Fig. 42 UK Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany Country Dynamics
  • Fig. 44 Germany Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 45 France Country Dynamics
  • Fig. 46 France Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy Country Dynamics
  • Fig. 48 Italy Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain Country Dynamics
  • Fig. 50 Spain Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Country Dynamics
  • Fig. 52 Norway Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden Country Dynamics
  • Fig. 54 Sweden Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark Country Dynamics
  • Fig. 56 Denmark Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan Country Dynamics
  • Fig. 59 Japan Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 60 China Country Dynamics
  • Fig. 61 China Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 62 India Country Dynamics
  • Fig. 63 India Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia Country Dynamics
  • Fig. 65 Australia Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea Country Dynamics
  • Fig. 67 South Korea Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand Country Dynamics
  • Fig. 69 Thailand Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil Country Dynamics
  • Fig. 72 Brazil Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina Country Dynamics
  • Fig. 74 Argentina Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa Country Dynamics
  • Fig. 77 South Africa Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia Country Dynamics
  • Fig. 79 Saudi Arabia Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE Country Dynamics
  • Fig. 81 UAE Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait Key Country Dynamics
  • Fig. 83 Kuwait Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework